Inicio › Cáncer de pulmón de células no pequeñas › Washington

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Washington

85 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Washington.

Ciudades en Washington

Texto oficial del estudio (inglés)

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Vista Oncology Inc PS, Olympia

ReclutandoFase 3

Edades de 18 a 100 · Todos los sexos · Actualizado el 13 nov 2026 · NCT05920356

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Virginia Mason Medical Center, Seattle

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07488676

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

American Oncology Network Vista Oncology Division-West office, Olympia
American Oncology Network Vista Oncology Division-East office, Olympia

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06758401

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Swedish Cancer Institute-Edmonds, Edmonds
Swedish Cancer Institute-Issaquah, Issaquah
Swedish Medical Center-First Hill, Seattle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06498635

BostonGene and Exigent Genomic INsight Study

Northwest Medical Specialities, Puyallup

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06272864

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Kadlec Clinic Hematology and Oncology, Kennewick
Valley Medical Center, Renton

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04267848

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Swedish Cancer Institute Medical Oncology, Edmonds

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06270706

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Northwest Medical Specialties - Gig Harbor, Gig Harbor
Northwest Medical Specialties - Puyallup Medical Oncology, Puyallup
Northwest Medical Specialties - Tacoma, Tacoma

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06472245

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Fred Hutchinson Cancer Research Center, Seattle

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04886804

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Virginia Mason Medical Center, Seattle

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07020221

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Medical Oncology Associates, Spokane

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07503808

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Local Institution - 0283, Seattle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07680790

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Tacoma

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07291037

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

MultiCare Regional Cancer Center, Auburn
MultiCare Regional Cancer Center, Gig Harbor
MultiCare Regional Cancer Center, Puyallup
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06216301

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Swedish Cancer Institute ( Site 0143), Seattle
St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192), Silverdale

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06623422

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Fred Hutchinson Cancer Center ( Site 3202), Seattle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07513376

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0515, Edmonds
Local Institution - 0499, Lacey
Local Institution - 0508, Seattle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06561386

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

American Oncology Network Vista Oncology Division-West office, Olympia
American Oncology Network Vista Oncology Division-East office, Olympia

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07144280

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Swedish Cancer Institute-Edmonds, Edmonds
Swedish Cancer Institute-Issaquah, Issaquah
Swedish Medical Center-First Hill, Seattle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07388524

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Swedish Cancer Institute - Edmonds, Edmonds
Swedish Medical Center, Seattle
Cancer Care Northwest - Vercler, Spokane Valley
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06890598

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Summit Cancer Center, Spokane

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06150664

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Fred Hutchinson Cancer Center, Seattle

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06706076

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Swedish Cancer Institute, Everett

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Kaiser Permanente Bellevue Medical Center, Bellevue
PeaceHealth Saint Joseph Medical Center, Bellingham
Swedish Cancer Institute-Edmonds, Edmonds
y 8 más

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06418204

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Swedish Cancer Institute - Edmonds, Edmonds
Kadlec Clinic Hematology and Oncology, Kennewick
Swedish Medical Center, Seattle
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06119581

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Fred Hutchinson Cancer Center, Seattle
University of Washington Medical Center - Montlake, Seattle

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT03191149

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Swedish Cancer Institute, Seattle

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05498428

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

Medical Oncology Associates - Summit Cancer Centers, Spokane

ReclutandoFase 3

Edades de 18 a 90 · Todos los sexos · Actualizado el 2 nov 2026 · NCT06745908

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Swedish Cancer Institute, Edmonds

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07185997

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT04613596

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA09-0, Puyallup
USA07-0, Spokane

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06953089

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Olympia
Research Site, Seattle
Research Site, Spokane
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06692738

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Valley Medical Center /ID# 253950, Renton

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT04928846

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Tacoma
Research Site, Vancouver
Research Site, Wenatchee

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT06357533

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Vista Oncology - East Olympia /ID# 275438, Olympia
Northwest Medical Specialties Tacoma /ID# 270469, Tacoma

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06772623

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Fred Hutchinson Cancer Center, Seattle

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT04981119

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Summit Cancer Treatment Center, Spokane

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT06899126

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Local Institution - 0384, Spokane

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT07361510

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Medical Oncology Associates - Spokane /ID# 277172, Spokane
Northwest Medical Specialties Tacoma /ID# 270534, Tacoma

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT06568939

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Edmonds
Research Site, Seattle

ReclutandoFase 2

Edades de 18 a 95 · Todos los sexos · Actualizado el 21 oct 2026 · NCT05061550

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.